Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in
slowing tumor activity in patients with advanced non-small cell lung cancer. The study is
also looking at the safety of S-1.
Phase:
Phase 2
Details
Lead Sponsor:
Taiho Oncology, Inc.
Collaborators:
Quintiles, Inc. United BioSource Corporation United BioSource, LLC